Targets › FN1
2 programs from 1 company in 9 trials: 6 Phase 2, 2 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.
Fibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. Fibronectins are involved in cell adhesion, cell motility, opsonization, wound healing, and maintenance of cell shape. (UniProt, P02751)
Open in Phaseline: the race on FN1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Philogen | L19IL2 Fibronectin binding agent | FN1 | Phase 3 | Malignant Melanoma; Melanoma Stage III; Locally Advanced Basal Cell Carcinoma; Locally Advanced Cutaneous Squamous Cell Carcinoma … | May 2028 |
| Philogen | IL12-L19L19 Antibody-cytokine fusion protein; IL-12 fused to L19 antibody targeting fibronectin | IL12A, IL12B, FN1 | Phase 1 | Advanced Solid Tumor | Dec 2026 |
Locally Advanced Basal Cell Carcinoma (3) Melanoma Stage III (2) Malignant Melanoma (1) Locally Advanced Cutaneous Squamous Cell Carcinoma (1) FAP (1) Advanced Solid Tumor (1)
small molecule (1), protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.